TB becomes life threatening when the drugs used for treatment develop resistance and are no longer effective or are rendered less effective against the germ Mycobacterium tuberculosis.
US FDA has approved new drug Bedaquiline which is also known as Sirturo which can be used to treat such patients who have developed multi drug resistant pulmonary tuberculosis (TB).
When mycobacterium tuberculosis develops resistance to isoniazid (INH) or rifampicin (RMP) the drugs used as first line of treatment it is called as multi drug resistant pulmonary tuberculosis (TB) . Usual the resistance is developed when cource of drug treatment is interrupted. The drug resistance is attributed to mutation over gene which is responsible for production of ATP, proton pump which is source of energy in the process of replication of Mycobacterium tuberculosis,
Drug Bedaquiline acts by inhabiting enzyme ATP synthase and brings about inhibition of replication of DNA the drug is capable of producing sterilizing effect on Mycobacterium tuberculosis infection. It should be used along with other drugs in treatment.
Bedaquiline is a diarylquinolone compound IUPAC Name (1R,2S)-1-(6-Bromo-2-methoxy-3-quinolyl)-4-dimethylamino-2-(1-naphthyl)-1-phenyl-butan-2-ol.
It was developed by scientist Koen Andries (University of Antwerp) ; working with Janssen Pharmaceuticals Belgium.
Side effect of the drug Bedaquiline (Sirturo) : It may produce cardiac arrhythmia, drug will be having a warning for this over its pack.
You may also like
New vaccine for TB which can even protect in late stage of infection and in TB infection relapsed form latent Mycobacterium tuberculosis (TB) infection.